Michael F. Reed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michael F. Reed has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Chan Shen
Department of Surgery, College of Medicine, The Pennsylvania State University, Hershey, PA 17033, USA
2 shared publications - Chandra Prakash Belani
Penn State Cancer Institute Penn State College of Medicine Hershey Pennsylvania USA
2 shared publications - Rolfy A. Perez Holguin
Division of Outcomes Research and Quality, Department of Surgery, Penn State Health Milton S. Hershey Medical Center, Hershey, PA USA
2 shared publications Alec Haas
The Pennsylvania State University College of Medicine, Hershey, Pennsylvania; Division of Thoracic Surgery, Department of Surgery, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania
1 shared publicationAntoine Delage
Institut Universitaire de Cardiologie et de Pneumologie de Québec, Hôpital Laval, Quebec, Canada; Université de Sherbrooke, Sherbrooke, Canada
1 shared publication- Charles Patrick
Department of Biomedical Engineering, Texas A&M University, College Station, USA
1 shared publication
Latest Publications
- Open Access
- 14 February 2024
- Published by Elsevier in Respiratory Medicine
- Vol. 224, 107565
Efficacy and safety of the Spiration Valve System™ for the treatment of severe emphysema in patients with Alpha-1 antitrypsin deficiency (EMPROVE)
- 14 February 2024
- Published by Elsevier in Respiratory Medicine
- Vol. 224, 107565
Open AccessEfficacy and safety of the Spiration Valve System™ for the treatment of severe emphysema in patients with Alpha-1 antitrypsin deficiency (EMPROVE)
- Open Access
- 9 April 2022
- Published by Springer Nature in BMC Health Services Research
- Vol. 22 (1) , 1-10
Utilization and costs of epidermal growth factor receptor mutation testing and targeted therapy in Medicare patients with metastatic lung adenocarcinoma
Guidelines in 2013 and 2014 recommended Epidermal Growth Factor Receptor (EGFR) testing for metastatic lung adenocarcinoma patients as the efficacy of targeted therapies depends on the mutations. However, adherence to these guidelines and the corresponding costs have not been well-studied. We identified 2362 patients at least 65 years old newly diagnosed with metastatic lung adenocarcinoma from January 2013 to December 2015 using the SEER-Medicare database. We examined the utilization patterns of EGFR testing and targeted therapies including erlotinib and afatinib. We further examined the costs of both EGFR testing and targeted therapy in terms of Medicare costs and patient out-of-pocket (OOP) costs. The EGFR testing rate increased from 38% in 2013 to 51% and 49% in 2014 and 2015 respectively. The testing rate was 54% among the 394 patients who received erlotinib, and 52% among the 42 patients who received afatinib. The median Medicare and OOP costs for testing were $1483 and $293. In contrast, the costs for targeted therapy were substantially higher with median 30-day costs at $6114 and $240 for erlotinib and $6239 and $471 for afatinib. This population-based study suggests that testing guidelines improved the use of EGFR testing, although there was still a large proportion of patients receiving targeted therapy without testing. The costs of targeted therapy were substantially higher than the testing costs, highlighting the need to improve adherence to testing guidelines in order to improve clinical outcomes while reducing the economic burden for both Medicare and patients.
- 9 April 2022
- Published by Springer Nature in BMC Health Services Research
- Vol. 22 (1) , 1-10
Open AccessUtilization and costs of epidermal growth factor receptor mutation testing and targeted therapy in Medicare patients with metastatic lung adenocarcinoma
Guidelines in 2013 and 2014 recommended Epidermal Growth Factor Receptor (EGFR) testing for metastatic lung adenocarcinoma patients as the efficacy of targeted therapies depends on the mutations. However, adherence to these guidelines and the corresponding costs have not been well-studied. We identified 2362 patients at least 65 years old newly diagnosed with metastatic lung adenocarcinoma from January 2013 to December 2015 using the SEER-Medicare database. We examined the utilization patterns of EGFR testing and targeted therapies including erlotinib and afatinib. We further examined the costs of both EGFR testing and targeted therapy in terms of Medicare costs and patient out-of-pocket (OOP) costs. The EGFR testing rate increased from 38% in 2013 to 51% and 49% in 2014 and 2015 respectively. The testing rate was 54% among the 394 patients who received erlotinib, and 52% among the 42 patients who received afatinib. The median Medicare and OOP costs for testing were $1483 and $293. In contrast, the costs for targeted therapy were substantially higher with median 30-day costs at $6114 and $240 for erlotinib and $6239 and $471 for afatinib. This population-based study suggests that testing guidelines improved the use of EGFR testing, although there was still a large proportion of patients receiving targeted therapy without testing. The costs of targeted therapy were substantially higher than the testing costs, highlighting the need to improve adherence to testing guidelines in order to improve clinical outcomes while reducing the economic burden for both Medicare and patients.
- 25 March 2022
- Published by Elsevier in Journal of Surgical Research
- Vol. 276, 160-167
Are Routine Chest Radiographs After Chest Tube Removal in Thoracic Surgery Patients Necessary?
- 25 March 2022
- Published by Elsevier in Journal of Surgical Research
- Vol. 276, 160-167
Are Routine Chest Radiographs After Chest Tube Removal in Thoracic Surgery Patients Necessary?
- 1 December 2013
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 96 (6) , 2225-2227
Endobronchial Valve Placement for Spontaneous Pneumothorax From Stage IIIA Non-Small Cell Lung Cancer Facilitates Neoadjuvant Therapy
- 1 December 2013
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 96 (6) , 2225-2227
Endobronchial Valve Placement for Spontaneous Pneumothorax From Stage IIIA Non-Small Cell Lung Cancer Facilitates Neoadjuvant Therapy